what type of investment is this? equity? interest only investment? any financial details would be helpful

Thank you for your interest in EndoSound. This is a convertible note. https://help.wefunder.com/#/contract/295251-convertible-note Once you click the reserve button, the terms of the convertible note can be found on the right-hand side. Here is a link: https://wefunder.com/endosound/invest Should you have any additional questions, please do not hesitate to reach out. The EndoSound Team

Hello Josh, I'm not particularly worried about your Debt Ratio of 199% at this stage of the company's lifecycle, just because with a Cash to Assets ratio of 47%, and future positive returns, the Debt Ratio can eventually be slashed down over time and eventually paid off with i...

Great question—happy to clarify. The reported 80% gross margin includes licensing revenue. When isolating product sales and excluding non-cash items like depreciation, as well as warranty reserves and inventory write-offs, our 2024 product gross margin was approximately 68%. Last year’s gross margin was impacted by early-stage commercialization factors, including lower purchasing volumes, higher inbound shipping costs, and the operational dynamics typical of a company in its first year of rev...

Since this is a convertible note, there isn’t a fixed share price at the time of investment. Instead, the investment will convert into equity during a Series B round—it will be at a 20% discount to that round’s share price or at a valuation cap of $45M, whichever provides the better conversion terms.

I am a pulmonologist, and I am familiar with EBUS. It appears that your device is a disposable product. What is the cost of the product, and is this a reimbursable expense to the endoscopy suite? Does Medicare recognized the importance of EBUS and reimburse enough to cover the...

Hi Howard, Thanks for your thoughtful question. While our platform is currently focused on GI applications, we are actively exploring EBUS as a potential addition to our portfolio and have already conducted some early technical feasibility work. To clarify our design: our system features a reusable ultrasound transducer (with no working channels), paired with a single-use device that connects the transducer to the endoscope and controls the needle—eliminating the need for an elevator mechanis...

Hi EndoSound Team, I’m Zac Stahlhut with D3VC, a venture fund specializing in investment crowdfunding. Our team is conducting its due diligence and has two follow-up questions regarding the clinical application of your technology. First, your materials highlight a significant ...

Hi Zac- I’m Steve Steinberg, co-founder and Chief Medical Officer for EndoSound. Thanks for your insightful questions: 1. Diagnostic Timeline: a. Abdominal Pain and Dyspepsia: 25 years ago, Anand Sahai and a group of equally prominent luminaries in EUS demonstrated a 40% “find” rate when endoscopic ultrasound was added to a traditional upper endoscopic exam (EGD)—conditions that would not have been discovered with the standard EGD alone. (EUS to detect evidence of pancreatic disease in patien...

Invest in EndoSound

Advancing Access to High-Impact Endoscopic Ultrasound in GI

$253,954

of a $50,000 goal

INVEST

min $100

INVESTMENT TERMS

Preferred Stock

$30M pre-money valuation $1.26 per share

endosound.com

Portland, OR

Notable Angel B2B Healthcare Hardware Biotech

Ask a Question

EndoSound

Quick facts

Investor memo sources

Team profiles

Featured investor profiles

$253,954

Ask